Ardent Health Partners/$ARDT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ardent Health Partners
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in services and technologies, Ardent is passionate about making healthcare easier to access.
Ticker
$ARDT
Sector
Primary listing
NYSE
Industry
Health Care Providers and Services
Headquarters
Employees
22,050
Website
ARDT Metrics
BasicAdvanced
$1.6B
6.75
$1.64
-
-
Price and volume
Market cap
$1.6B
52-week high
$17.34
52-week low
$10.47
Average daily volume
426K
Financial strength
Current ratio
2.122
Quick ratio
1.532
Long term debt to equity
144.647
Total debt to equity
145.497
Interest coverage (TTM)
6.56%
Profitability
EBITDA (TTM)
544.166
Gross margin (TTM)
57.32%
Net profit margin (TTM)
3.73%
Operating margin (TTM)
6.59%
Effective tax rate (TTM)
17.83%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
5.22%
Return on equity (TTM)
23.35%
Valuation
Price to earnings (TTM)
6.75
Price to revenue (TTM)
0.25
Price to book
1.35
Price to tangible book (TTM)
7.14
Price to free cash flow (TTM)
12.703
Free cash flow yield (TTM)
7.87%
Free cash flow per share (TTM)
0.871
Growth
Revenue change (TTM)
8.91%
Earnings per share change (TTM)
935.53%
Bulls say / Bears say
Ardent Health reported a Q1 2025 revenue increase of 4% to $1.5 billion, meeting consensus expectations, with adjusted EBITDA rising to $98 million, surpassing market analyst expectations by $2 million. (Investing.com)
The company has been assigned a consensus 'Buy' rating by 13 research firms, with an average 12-month target price of $20.58, indicating analyst confidence in its growth potential. (Techdows News)
Ardent Health's rebranding to Ardent Health, Inc. reflects a strategic move to unify its brand identity, potentially enhancing market recognition and investor confidence. (Nasdaq)
Morgan Stanley downgraded Ardent Health's price target from $23.50 to $22.00, reflecting a more cautious outlook on the company's stock performance. (Defense World)
Bank of America downgraded Ardent Health from a 'Buy' to a 'Neutral' rating, reducing the price target from $22.00 to $19.00, indicating concerns about the company's near-term growth prospects. (Defense World)
The company's stock price has experienced volatility, with shares gapping up following an earnings beat but subsequently trading lower, suggesting potential instability in investor sentiment. (Defense World)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
ARDT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ardent Health Partners stock?
Ardent Health Partners (ARDT) has a market cap of $1.6B as of July 29, 2025.
What is the P/E ratio for Ardent Health Partners stock?
The price to earnings (P/E) ratio for Ardent Health Partners (ARDT) stock is 6.75 as of July 29, 2025.
Does Ardent Health Partners stock pay dividends?
No, Ardent Health Partners (ARDT) stock does not pay dividends to its shareholders as of July 29, 2025.
When is the next Ardent Health Partners dividend payment date?
Ardent Health Partners (ARDT) stock does not pay dividends to its shareholders.
What is the beta indicator for Ardent Health Partners?
Ardent Health Partners (ARDT) does not currently have a Beta indicator.